The Nebraska Cancer Research Center
Since 1984, The Nebraska Cancer Research Center has been a leader in cancer research, providing local access to National Cancer Institute-sponsored cancer clinical trials. Over 1,900 volunteers have participated in treatment, prevention and control trials through NCRC, helping to identify more effective cancer treatments and improve the quality of life of cancer patients.
Thanks to all who attended our "Colors of Hope: Cancer Research Fundraiser" on September 24, 2015. We are pleased to announce that we raised over $19,000 for cancer research as a result of your generosity.
We would also like to thank our sponsors:
Southeast Nebraska Cancer Center
Nebraska Hematology Oncology, PC
- Posted by Jeri on 06/04/2014
- Posted by Jeri on 05/21/2014
- Posted by Jeri on 02/21/2014
WHAT IS A CLINICAL TRIAL?
New Clinical TrialsView all clinical trials available at NCRC.
EA6134: Advanced Mutant Melanoma - A Randomized Phase III trial of Dabrafenib + Trametinib followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab followed by Dabrafenib + Trametinib at Progression in Patients With Advanced BRAFV600 Mutant Melanoma.
Alliance A031201: Metastatic Prostate Cancer - Phase III Trial of Enzalutamide Versus Enzalutamide, Abiraterone and Prednisone for castration resistant metastatic prostate cancer.
S1300: Non-Squamous Cell Lung Cancer - A Randomized, Phase II Trial of Crizotinib Plus Pemetrexed Versus Pemetrexed Monotherapy in ALK-Positive Non-Squamous NSCLC Patients Who Have Progressed Systematically After Previous Clinical Benefit From Crizotinib Monotherapy.
S1404: A Phase III Randomized Trial Comparing High Dose Interferon to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma.